炔雌醇环丙孕酮片联合二甲双胍对PCOS患者排卵的影响
|
摘要
目的探究多囊卵巢综合征患者接受达英-35与二甲双胍联合治疗的价值。方法以多囊卵巢综合征患者为研究对象,例数为100例,时间为2016年1月—2018年1月,采用分段随机化法分组,其中对照组实施达英-35治疗,试验组则实施达英-35与二甲双胍联合治疗,分析2组多囊卵巢综合征患者治疗的结果。结果两组治疗后的睾酮、黄体生成素、基础卵泡刺激素、催乳素水平均较治疗前显著改善,其中试验组治疗后的睾酮、黄体生成素水平明显优于对照组(P <0.05);试验组的排卵率明显高于对照组,差异具有统计学意义(P <0.05)。结论相比达英-35单药治疗,多囊卵巢综合征患者接受达英-35与二甲双胍联合治疗,可更有效降低睾酮和黄体生成素水平。
Objective To explore the value of polycystic ovary syndrome(PCOS) patients receiving combination therapy of ethinylestradiol and metformin. Methods In patients with polycystic ovary syndrome as the research object, the number of cases of 100 cases, from January 2016 to January 2018, grouped by segmentation randomized method, including the control implementation ethinylestradiol cyproterone treatment, the experimental group was implemented ethinylestradiol and cyproterone metformin combination therapy, and analyzed the results of two groups treatment in patients with polycystic ovary syndrome. Results The levels of testosterone, luteinizing hormone, basal follicle stimulating hormone and prolactin in the two groups were significantly improved compared with those before treatment. The testosterone and luteinizing hormone levels in the experimental group were significantly better than those in the control group(P < 0.05). The ovulation rate of the experimental group was significantly higher than that of the control group, and the difference was statistically significant(P < 0.05). Conclusion Compared with ethinyl estradiol cyproterone tablets alone, patients with polycystic ovary syndrome receive ethinyl estradiol cyproterone tablets in combination with metformin, which can reduce testosterone and luteinizing hormone levels more effectively.
Objective To explore the value of polycystic ovary syndrome(PCOS) patients receiving combination therapy of ethinylestradiol and metformin. Methods In patients with polycystic ovary syndrome as the research object, the number of cases of 100 cases, from January 2016 to January 2018, grouped by segmentation randomized method, including the control implementation ethinylestradiol cyproterone treatment, the experimental group was implemented ethinylestradiol and cyproterone metformin combination therapy, and analyzed the results of two groups treatment in patients with polycystic ovary syndrome. Results The levels of testosterone, luteinizing hormone, basal follicle stimulating hormone and prolactin in the two groups were significantly improved compared with those before treatment. The testosterone and luteinizing hormone levels in the experimental group were significantly better than those in the control group(P < 0.05). The ovulation rate of the experimental group was significantly higher than that of the control group, and the difference was statistically significant(P < 0.05). Conclusion Compared with ethinyl estradiol cyproterone tablets alone, patients with polycystic ovary syndrome receive ethinyl estradiol cyproterone tablets in combination with metformin, which can reduce testosterone and luteinizing hormone levels more effectively.
引文
[1]蔡艳悦,金敏娟.探讨多囊卵巢综合征采用达英-35片联合二甲双胍治疗疗效及其对胰岛素抵抗、激素影响[J].中国生化药物杂志,2016,36(3):67-69.
[2]李青青.二甲双胍联合达英-35治疗多囊卵巢综合征不孕症的临床观察[J].现代仪器与医疗,2015,21(2):103-104.
[3]张慧,王瑞玲,李群英,等.二甲双胍与达英-35治疗多囊卵巢综合征的疗效及对性激素、血糖水平的影响[J].疑难病杂志,2016,15(6):621-624.
[4]林琼林.坤泰胶囊联合达英-35片和二甲双胍治疗多囊卵巢综合征的临床研究[J].现代药物与临床,2016,31(3):338-341.
[5]李晓燕,张蓓,林莉,等.达英-35分别联合二甲双胍、吡格列酮治疗多囊卵巢综合征的疗效和安全性比较[J].中国药房,2016,27(36):5073-5075.
[6]王治鸿,刘翔华,张红梅,等.来曲唑联合达英-35片二甲双胍治疗耐克罗米芬性多囊卵巢综合征的临床研究[J].中国药物与临床,2016,16(6):788-791.
[7]Mumm H,Jensen DM,S?rensen JA,et al.Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes[J].Acta Obstet Gynecol Scand,2015,94(2):204-211.
[8]张彩宇,陶爱群,莫有珍,等.二甲双胍与达英-35片联用对多囊卵巢综合征患者相关激素分泌水平的影响[J].中国现代医学杂志,2016,26(9):85-88.
[9]史晓雪,任秀朋,闫冰,等.达英-35联合二甲双胍或吡格列酮治疗育龄期多囊卵巢综合征并胰岛素抵抗效果比较[J].中国药业,2018,27(10):32-35.
[10]赵松青,方成霞,刘正华,等.达英-35联合二甲双胍对多囊卵巢综合征患者内分泌及糖脂代谢的影响[J].徐州医学院学报,2016,36(9):578-581.
[11]Christ JP,Vanden Brink H1,Brooks ED.et al.Ultrasound features of polycystic ovaries relate to degree of reproductive and metabolic disturbance in polycystic ovary syndrome[J].Fertil Steril,2015,103(3):787-794.
[12]李媛媛,潘晓莲,周妙蕾,等.二甲双胍联合达英-35治疗青春期多囊卵巢综合征的疗效及对患者卵巢功能的影响[J].中国基层医药,2018,25(18):2406-2408.
[13]张新花,寇立巧,张静,等.温肾促排汤联合达英-35、二甲双胍对多囊卵巢综合征患者糖脂代谢的影响[J].医疗装备,2016,29(3):157-159.
[14]杨滢,尹家瑶.二甲双胍联合达英-35对多囊卵巢综合征患者性激素水平、胰岛功能、排卵和妊娠影响[J].临床误诊误治,2018,31(2):73-76.
[15]鲍旭东,徐杨,傅荣,等.达英-35联合二甲双胍对多囊卵巢综合征不孕症患者激素水平的影响[J].实用临床医药杂志,2018,22(1):104-106,110.
[2]李青青.二甲双胍联合达英-35治疗多囊卵巢综合征不孕症的临床观察[J].现代仪器与医疗,2015,21(2):103-104.
[3]张慧,王瑞玲,李群英,等.二甲双胍与达英-35治疗多囊卵巢综合征的疗效及对性激素、血糖水平的影响[J].疑难病杂志,2016,15(6):621-624.
[4]林琼林.坤泰胶囊联合达英-35片和二甲双胍治疗多囊卵巢综合征的临床研究[J].现代药物与临床,2016,31(3):338-341.
[5]李晓燕,张蓓,林莉,等.达英-35分别联合二甲双胍、吡格列酮治疗多囊卵巢综合征的疗效和安全性比较[J].中国药房,2016,27(36):5073-5075.
[6]王治鸿,刘翔华,张红梅,等.来曲唑联合达英-35片二甲双胍治疗耐克罗米芬性多囊卵巢综合征的临床研究[J].中国药物与临床,2016,16(6):788-791.
[7]Mumm H,Jensen DM,S?rensen JA,et al.Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes[J].Acta Obstet Gynecol Scand,2015,94(2):204-211.
[8]张彩宇,陶爱群,莫有珍,等.二甲双胍与达英-35片联用对多囊卵巢综合征患者相关激素分泌水平的影响[J].中国现代医学杂志,2016,26(9):85-88.
[9]史晓雪,任秀朋,闫冰,等.达英-35联合二甲双胍或吡格列酮治疗育龄期多囊卵巢综合征并胰岛素抵抗效果比较[J].中国药业,2018,27(10):32-35.
[10]赵松青,方成霞,刘正华,等.达英-35联合二甲双胍对多囊卵巢综合征患者内分泌及糖脂代谢的影响[J].徐州医学院学报,2016,36(9):578-581.
[11]Christ JP,Vanden Brink H1,Brooks ED.et al.Ultrasound features of polycystic ovaries relate to degree of reproductive and metabolic disturbance in polycystic ovary syndrome[J].Fertil Steril,2015,103(3):787-794.
[12]李媛媛,潘晓莲,周妙蕾,等.二甲双胍联合达英-35治疗青春期多囊卵巢综合征的疗效及对患者卵巢功能的影响[J].中国基层医药,2018,25(18):2406-2408.
[13]张新花,寇立巧,张静,等.温肾促排汤联合达英-35、二甲双胍对多囊卵巢综合征患者糖脂代谢的影响[J].医疗装备,2016,29(3):157-159.
[14]杨滢,尹家瑶.二甲双胍联合达英-35对多囊卵巢综合征患者性激素水平、胰岛功能、排卵和妊娠影响[J].临床误诊误治,2018,31(2):73-76.
[15]鲍旭东,徐杨,傅荣,等.达英-35联合二甲双胍对多囊卵巢综合征不孕症患者激素水平的影响[J].实用临床医药杂志,2018,22(1):104-106,110.